Search - tctmd.com

Displaying 1 - 20 of 44

Sort: Relevancy | Date

News Conference News ESC 2025

Digitoxin Cuts Risk in Well-Treated HFrEF Patients: DIGIT-HF

Michael O'Riordan

August 29, 2025

News Daily News

Key Subgroups of HF Patients Missing Out on SGLT2 Inhibitors: Registry Data

L.A. McKeown

July 24, 2025

News Daily News

Finerenone Cuts Intensification of Oral Diuretics in Outpatient Setting: FINEARTS-HF

Michael O'Riordan

March 03, 2025

News Conference News ESC 2024

FINEARTS-HF: Benefit of Finerenone Extends to HFmrEF and HFpEF Patients

Michael O'Riordan

September 01, 2024

News Opinion CV Team Dispatch

August 2024 Dispatch for the CV Team

L.A. McKeown

August 01, 2024

News Daily News

Reduced Vascular Load, Better RV Function With Dapagliflozin in HFpEF

Michael O'Riordan

July 26, 2024

News Conference News ACC 2024

Most HFrEF Patients Eligible for Quadruple Therapy, but Few Get It

Michael O'Riordan

March 27, 2024

News Conference News ESC 2023

ESC Focused Update on HF Synthesizes New Trial Data for Practical Use

L.A. McKeown

September 01, 2023

News Conference News ESC 2023

New ESC Guidelines for CVD in Patients With Diabetes Cover Wide Ground

Caitlin E. Cox

August 30, 2023

News ESC 2023

Qiliqiangxin, a Traditional Chinese Medication, Cuts CV Events in HF: QUEST

Michael O'Riordan

August 27, 2023

News Daily News

SGLT2i May Be Helpful Early After Acute MI in Diabetic Patients

Todd Neale

July 17, 2023

News Daily News

New Expert Consensus Papers Aim to Boost Management, Outcomes in HFpEF

L.A. McKeown

April 19, 2023

News Daily News

Borderline Cost-effectiveness for SGLT2 Inhibitors in HFpEF

Todd Neale

March 15, 2023

News Daily News

HFrEF’s Financial Burden May Get Relief From Inflation Reduction Act

L.A. McKeown

January 13, 2023

News Daily News

Analysis Cements Benefits of SGLT2 Inhibitors in HF, but Diabetes Matters for Deaths

Michael O'Riordan

December 08, 2022

News Conference News AHA 2022

EMPA-KIDNEY: Empagliflozin a ‘Win’ for Patients With CKD

Todd Neale

November 06, 2022

News Opinion Editor's Corner ESC 2022

What’s Going to Be Hot at ESC 2022?

Shelley Wood

August 22, 2022

News Daily News

Dapagliflozin Safe, Effective in Diabetes Regardless of Background CV Meds

Shelley Wood

July 25, 2022

News Conference News ESC Heart Failure 2022

Dapagliflozin Boosts Health Status Across LVEF Range

Shelley Wood

May 23, 2022

News Daily News

DELIVER Trial Scores a Win for Dapagliflozin in HFpEF

L.A. McKeown

May 05, 2022

Advertisement

Digitoxin Cuts Risk in Well-Treated HFrEF Patients: DIGIT-HF

Key Subgroups of HF Patients Missing Out on SGLT2 Inhibitors: Registry Data

Finerenone Cuts Intensification of Oral Diuretics in Outpatient Setting: FINEARTS-HF

FINEARTS-HF: Benefit of Finerenone Extends to HFmrEF and HFpEF Patients

August 2024 Dispatch for the CV Team

Reduced Vascular Load, Better RV Function With Dapagliflozin in HFpEF

Most HFrEF Patients Eligible for Quadruple Therapy, but Few Get It

ESC Focused Update on HF Synthesizes New Trial Data for Practical Use

New ESC Guidelines for CVD in Patients With Diabetes Cover Wide Ground

Qiliqiangxin, a Traditional Chinese Medication, Cuts CV Events in HF: QUEST

SGLT2i May Be Helpful Early After Acute MI in Diabetic Patients

New Expert Consensus Papers Aim to Boost Management, Outcomes in HFpEF

Borderline Cost-effectiveness for SGLT2 Inhibitors in HFpEF

HFrEF’s Financial Burden May Get Relief From Inflation Reduction Act

Analysis Cements Benefits of SGLT2 Inhibitors in HF, but Diabetes Matters for Deaths

EMPA-KIDNEY: Empagliflozin a ‘Win’ for Patients With CKD

What’s Going to Be Hot at ESC 2022?

Dapagliflozin Safe, Effective in Diabetes Regardless of Background CV Meds

Dapagliflozin Boosts Health Status Across LVEF Range

DELIVER Trial Scores a Win for Dapagliflozin in HFpEF

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content